Skip to content

Evaluation of the Aspheric ReSTOR IOL After Routine Cataract Extraction

Evaluation of the Aspheric ReSTOR IOL After Routine Cataract Extraction

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00720005
Enrollment
20
Registered
2008-07-22
Start date
2007-09-30
Completion date
2008-12-31
Last updated
2010-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract

Keywords

Cataract, cataract extraction, intraocular lens, age related

Brief summary

The purpose of this study is to evaluate the visual outcomes and patient satisfaction after bilateral implantation of the aspheric ReSTOR multifocal intraocular lens (IOL) and compare it to a historical control group of patients implanted bilaterally with the spherical ReSTOR multifocal

Detailed description

The purpose of this study is to evaluate the visual outcomes and patient satisfaction after bilateral implantation of the aspheric ReSTOR multifocal intraocular lens (IOL) and compare it to a historical control group of patients implanted bilaterally with the spherical ReSTOR multifocal.

Interventions

DEVICEAspheric Acrysof ReSTOR intraocular lens

Bilateral implantation of Aspheric Acrysof ReSTOR

Sponsors

Medical University of South Carolina
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Subject must have an age-related cataract in both eyes. * 40 years of age or older. * Patient must desire cataract extraction. * Expected maximum of 2 weeks and minimum of 1-week interval between first and second eye surgeries. * Willing and able to comply with scheduled visits and other study procedures

Exclusion criteria

* Preoperative ocular pathology potentially affecting visual acuity. * Keratometric astigmatism exceeding 1.50 diopters. * Planned postoperative refraction for mono-vision. * Uncontrolled diabetes. * Use of any systemic or topical drug known to interfere with visual performance. * Contact lens use during the active treatment portion of the trial. * Any concurrent infectious/non infectious conjunctivitis, keratitis or uveitis. * Pregnant or nursing mothers and females of childbearing potential not practicing a reliable and medically acceptable method of birth control. * Any clinically significant, serious or severe medical or psychiatric condition that may increase the risk associated with study participation or study device implantation or may interfere with the interpretation of study results. * Participation in (or current participation) any investigational drug or device trial within the previous 30 days prior to the start date of this trial. * Intraocular conventional surgery within the past three months or intraocular laser surgery within one month in the operated eye. * Other ocular surgery at the time of the cataract extraction.

Design outcomes

Primary

MeasureTime frame
ETDRS uncorrected and best corrected visual acuity at distance, intermediate, and near, manifest refraction, distance corrected near visual acuity (DCNVA), and best near point (optimal reading distance).Preoperatively, 1, 3 and 6 months postoperatively

Secondary

MeasureTime frame
pupil size and contrast sensitivity under photopic and mesopic conditions wearing the best distance correction (the latter per eye and both eyes. Slit-lamp exam, eye dominance, reading speed test, and a quality of vision questionnaire.preoperatively, 1, 3, 6 month

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026